Atlas Trials

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Clinical trial NCT04254978 · COMPLETED

Trial details

NCT number
NCT04254978
Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Essential Thrombocythemia
Start date
2020-09-08
Primary completion
2023-03-23
Enrollment
73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.